Linike Medical Group Ltd

FRC's fair value estimate for Linike Medical Group Ltd, and the rating behind it. LNMG last traded at $0.03, 4.1× trailing earnings — the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.

Valuation, profitability, liquidity and leverage ratios for Linike Medical Group Ltd. Starting points for Linike Medical Group Ltd: P/E 4.1, beta -6.75 — an Specialty Retail name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.

Dividend history, yield and payout sustainability for Linike Medical Group Ltd. Linike Medical Group Ltd does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.

Reported vs. expected earnings history for Linike Medical Group Ltd. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.

Income statement, balance sheet and cash flow history for Linike Medical Group Ltd. Linike Medical Group Ltd has reported as a listed company since 2012. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.

Linike Medical Group Ltd valued side by side against its closest peers. Linike Medical Group Ltd is measured against Specialty Retail peers within the Consumer Cyclical sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.

Which institutions hold Linike Medical Group Ltd, and how their positions are changing. At a $13.1M market value, institutional positions materially move Linike Medical Group Ltd's register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.

Buying and selling by Linike Medical Group Ltd executives and directors. Shares of Linike Medical Group Ltd have traded between $0.0028 and $0.06 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.

U.S. Senate disclosures naming Linike Medical Group Ltd. Linike Medical Group Ltd is a $13.1M Consumer Cyclical company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.

U.S. House of Representatives disclosures naming Linike Medical Group Ltd. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.

Latest headlines and company announcements for Linike Medical Group Ltd. Coverage tracks Linike Medical Group Ltd within Specialty Retail (Consumer Cyclical). Press releases and market coverage, newest first.